NASDAQ:SABS SAB Biotherapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. 1.50 +0.27 (+21.95%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range1.27▼1.6350-Day Range1.11▼2.7652-Week Range1.11▼12.90Volume146,700 shsAverage Volume53,642 shsMarket Capitalization$64.44 millionP/E RatioN/ADividend YieldN/APrice Target17.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SABS Stock Forecast (MarketRank)Overall MarketRank™1.83 out of 5 starsMedical Sector743rd out of 1,411 stocksBiological Products, Except Diagnostic Industry121st out of 215 stocksAnalyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingSAB Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of 17.00, SAB Biotherapeutics has a forecasted upside of 1,033.3% from its current price of 1.50.Amount of Analyst CoverageSAB Biotherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Community Rank Outperform VotesSAB Biotherapeutics has received 6 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSAB Biotherapeutics has received 4 “underperform” votes. (Add your “underperform” vote.)Community SentimentSAB Biotherapeutics has received 60.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about SAB Biotherapeutics and other stocks. Vote “Outperform” if you believe SABS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SABS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSAB Biotherapeutics does not currently pay a dividend.Dividend GrowthSAB Biotherapeutics does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders42.00% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.25% of the stock of SAB Biotherapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for SAB Biotherapeutics are expected to decrease in the coming year, from -0.43 to -0.61 per share.Price to Book Value per Share RatioSAB Biotherapeutics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SAB Biotherapeutics (NASDAQ:SABS)SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.Read More SABS Stock News HeadlinesJune 13, 2022 | americanbankingnews.comSAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives 17.00 Average Price Target from AnalystsJune 6, 2022 | finance.yahoo.comSAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical OfficerJune 4, 2022 | americanbankingnews.comSAB Biotherapeutics (NASDAQ:SABS) Stock Rating Lowered by Zacks Investment ResearchJune 2, 2022 | americanbankingnews.comSAB Biotherapeutics (NASDAQ:SABS) Upgraded to "Buy" by Zacks Investment ResearchMay 31, 2022 | finance.yahoo.comSAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering SummitMay 31, 2022 | finance.yahoo.comSAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering SummitMay 14, 2022 | seekingalpha.comSAB Biotherapeutics GAAP EPS of $0.02May 13, 2022 | finance.yahoo.comSAB Biotherapeutics Provides Company Update for Q1 2022 Financial ResultsMay 12, 2022 | finance.yahoo.comSAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment ConferenceMay 5, 2022 | finance.yahoo.comShareholders in SAB Biotherapeutics (NASDAQ:SABS) are in the red if they invested a year agoApril 5, 2022 | finance.yahoo.comSAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific AdvisorsApril 5, 2022 | finance.yahoo.comSAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific AdvisorsMarch 29, 2022 | finance.yahoo.comSAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial ResultsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SABS CUSIPN/A CIK1833214 Webwww.bigcypressaccorp.com Phone305-204-3338FaxN/AEmployees139Year FoundedN/ACompany Calendar Today6/26/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast17.00 High Stock Price Forecast23.00 Low Stock Price Forecast7.00 Forecasted Upside/Downside+1,033.3%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17.15 million Net MarginsN/A Pretax Margin-31.35% Return on Equity-134.64% Return on Assets-26.70% Debt Debt-to-Equity Ratio0.09 Current Ratio1.98 Quick Ratio1.98 Sales & Book Value Annual Sales$60.88 million Price / Sales1.06 Cash FlowN/A Price / Cash FlowN/A Book Value0.89 per share Price / Book1.69Miscellaneous Outstanding Shares42,960,000Free Float24,918,000Market Cap$64.44 million OptionableNot Optionable Beta0.59 SAB Biotherapeutics Frequently Asked Questions Should I buy or sell SAB Biotherapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SAB Biotherapeutics stock. View analyst ratings for SAB Biotherapeutics or view top-rated stocks. What is SAB Biotherapeutics' stock price forecast for 2022? 3 brokerages have issued 12 month target prices for SAB Biotherapeutics' stock. Their SABS stock forecasts range from 7.00 to 23.00. On average, they predict SAB Biotherapeutics' share price to reach 17.00 in the next year. This suggests a possible upside of 1,033.3% from the stock's current price. View analysts' price targets for SAB Biotherapeutics or view top-rated stocks among Wall Street analysts. How has SAB Biotherapeutics' stock performed in 2022? SAB Biotherapeutics' stock was trading at 7.81 on January 1st, 2022. Since then, SABS stock has decreased by 80.8% and is now trading at 1.50. View the best growth stocks for 2022 here. When is SAB Biotherapeutics' next earnings date? SAB Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for SAB Biotherapeutics. Who are SAB Biotherapeutics' key executives? SAB Biotherapeutics' management team includes the following people: Mr. Samuel J. Reich, Exec. Chairman (Age 47, Pay $212.58k)Dr. Eddie Joe Sullivan Ph.D., Co-Founder, Pres, CEO & Director (Age 56, Pay $526.82k)Ms. Christine E. Hamilton M.B.A., Co-Founder & Independent Director (Age 66, Pay $25k)Dr. Edward D. Hamilton D.V.M., Co-Founder & Board ObserverMr. Russell P. Beyer C.M.A., Chief Financial Officer (Age 67)Dr. Christoph Bausch Ph.D., Chief Operating Officer (Age 51)Dr. Carlos N. Carillo Ph.D., Sr. VP of Regulatory Affairs Who are some of SAB Biotherapeutics' key competitors? Some companies that are related to SAB Biotherapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of SABS's competitors. What is SAB Biotherapeutics' stock symbol? SAB Biotherapeutics trades on the NASDAQ under the ticker symbol "SABS." Who are SAB Biotherapeutics' major shareholders? SAB Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.68%), State Street Corp (0.10%) and Qube Research & Technologies Ltd (0.06%). Which institutional investors are buying SAB Biotherapeutics stock? SABS stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, and Qube Research & Technologies Ltd. How do I buy shares of SAB Biotherapeutics? Shares of SABS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SAB Biotherapeutics' stock price today? One share of SABS stock can currently be purchased for approximately 1.50. How much money does SAB Biotherapeutics make? SAB Biotherapeutics (NASDAQ:SABS) has a market capitalization of $64.44 million and generates $60.88 million in revenue each year. How many employees does SAB Biotherapeutics have? SAB Biotherapeutics employs 139 workers across the globe. How can I contact SAB Biotherapeutics? SAB Biotherapeutics' mailing address is 300 W. 41ST STREET SUITE 202, MIAMI BEACH FL, 33140. The official website for SAB Biotherapeutics is www.bigcypressaccorp.com. The company can be reached via phone at 305-204-3338 or via email at [email protected]. This page (NASDAQ:SABS) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
